04.30.15
Sanofi
1Q Revenues: €8.8 billion (+12%)
1Q Earnings: €1.1 billion (flat)
Comments: Pharmaceutical sales were €7.5 billion, up 2% at Constant Exchange Rates (CER). Diabetes sales were €1.8 billion, down 3% reflecting expected pricing impact on Lantus in the U.S.Vaccines sales were €697 million, down 5% due to expected delay in Southern Hemisphere influenza campaign. Genzyme sales were €821 million, up 31% mainly driven by Aubagio.Animal Health sales were up 14% driven by NexGard.
1Q Revenues: €8.8 billion (+12%)
1Q Earnings: €1.1 billion (flat)
Comments: Pharmaceutical sales were €7.5 billion, up 2% at Constant Exchange Rates (CER). Diabetes sales were €1.8 billion, down 3% reflecting expected pricing impact on Lantus in the U.S.Vaccines sales were €697 million, down 5% due to expected delay in Southern Hemisphere influenza campaign. Genzyme sales were €821 million, up 31% mainly driven by Aubagio.Animal Health sales were up 14% driven by NexGard.